论文部分内容阅读
目的:评价瑞舒伐他汀10mg·d-1对国人调脂作用的有效性和安全性。方法:从万方数据库、中国期刊网全文数据库、维普全文电子期刊中检索2001～2008年的相关文献,比较应用瑞舒伐他汀10mg·d-1前、后血脂的变化,并利用RevMan4.2对数据进行Meta分析,同时对其安全性作出评价。结果:5项研究共346例患者入选,经瑞舒伐他汀10mg·d-1治疗后低密度脂蛋白胆固醇(LDL-C)平均降低1.71mmol·L-1,总胆固醇(TC)平均降低1.98mmol·L-1,高密度脂蛋白胆固醇(HDL-C)平均升高0.17mmol·L-1,甘油三酯(TG)平均降低0.79mmol·L-1。共报道了54例不良事件,主要为轻微的上呼吸道感染症状、轻微背痛、轻微乏力和轻微胃肠道不适,均未出现严重的不良反应。结论:瑞舒伐他汀10mg·d-1在国内的临床研究治疗中疗效和安全性均较好。
Objective: To evaluate the efficacy and safety of rosuvastatin 10 mg · d-1 on Chinese people’s lipid-lowering effect. Methods: The related literatures from 2001 to 2008 were retrieved from Wanfang database, Chinese Journal Full-text Database, VIP full-text electronic journals, and the changes of blood lipid before and after rosiglitazone 10 mg · d-1 were compared. RevMan4.2 Meta-analysis of the data, while evaluating its safety. RESULTS: A total of 346 patients were enrolled in 5 studies. The average LDL-C level decreased by 1.71 mmol·L-1 after treatment with 10 mg · d-1 rosuvastatin, while the total cholesterol (TC) decreased by 1.98 mmol·L-1, high-density lipoprotein cholesterol (HDL-C) increased by 0.17mmol·L-1 and triglyceride (TG) decreased by 0.79mmol·L-1. Reported a total of 54 cases of adverse events, mainly minor upper respiratory tract infection symptoms, mild back pain, mild fatigue and mild gastrointestinal discomfort, did not appear serious adverse reactions. Conclusion: Rosuvastatin 10mg · d-1 in clinical trials in the treatment of efficacy and safety are better.